Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

PI3K-dependent phosphorylation of Fbw7 modulates substrate degradation and activity.

Schülein C, Eilers M, Popov N.

FEBS Lett. 2011 Jul 21;585(14):2151-7. doi: 10.1016/j.febslet.2011.05.036. Epub 2011 May 24.

2.

Preclinical models for neuroblastoma: establishing a baseline for treatment.

Teitz T, Stanke JJ, Federico S, Bradley CL, Brennan R, Zhang J, Johnson MD, Sedlacik J, Inoue M, Zhang ZM, Frase S, Rehg JE, Hillenbrand CM, Finkelstein D, Calabrese C, Dyer MA, Lahti JM.

PLoS One. 2011 Apr 29;6(4):e19133. doi: 10.1371/journal.pone.0019133.

3.

Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha.

Qing G, Skuli N, Mayes PA, Pawel B, Martinez D, Maris JM, Simon MC.

Cancer Res. 2010 Dec 15;70(24):10351-61. doi: 10.1158/0008-5472.CAN-10-0740. Epub 2010 Oct 20.

4.

PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.

Bender A, Opel D, Naumann I, Kappler R, Friedman L, von Schweinitz D, Debatin KM, Fulda S.

Oncogene. 2011 Jan 27;30(4):494-503. doi: 10.1038/onc.2010.429. Epub 2010 Sep 20.

PMID:
20856197
5.

The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.

Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW.

Clin Cancer Res. 2010 Jul 15;16(14):3628-38. doi: 10.1158/1078-0432.CCR-09-3022. Epub 2010 Jul 6.

6.

Targeting the tumour vasculature: insights from physiological angiogenesis.

Chung AS, Lee J, Ferrara N.

Nat Rev Cancer. 2010 Jul;10(7):505-14. doi: 10.1038/nrc2868. Review.

PMID:
20574450
7.

Recent advances in neuroblastoma.

Maris JM.

N Engl J Med. 2010 Jun 10;362(23):2202-11. doi: 10.1056/NEJMra0804577. Review. No abstract available.

8.

Mcl1 becomes ubiquitin-ous: new opportunities to antagonize a pro-survival protein.

Hogarty MD.

Cell Res. 2010 Apr;20(4):391-3. doi: 10.1038/cr.2010.37. No abstract available.

PMID:
20357805
9.

The N-Myc-DLL3 cascade is suppressed by the ubiquitin ligase Huwe1 to inhibit proliferation and promote neurogenesis in the developing brain.

Zhao X, D' Arca D, Lim WK, Brahmachary M, Carro MS, Ludwig T, Cardo CC, Guillemot F, Aldape K, Califano A, Iavarone A, Lasorella A.

Dev Cell. 2009 Aug;17(2):210-21. doi: 10.1016/j.devcel.2009.07.009.

10.

Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.

Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R, Christiansen H, Berwanger B, Eilers M.

Cancer Cell. 2009 Jan 6;15(1):67-78. doi: 10.1016/j.ccr.2008.12.005.

11.

FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.

Mao JH, Kim IJ, Wu D, Climent J, Kang HC, DelRosario R, Balmain A.

Science. 2008 Sep 12;321(5895):1499-502. doi: 10.1126/science.1162981.

12.

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.

Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, García-Echeverría C, Maira SM.

Cancer Res. 2008 Aug 15;68(16):6598-607. doi: 10.1158/0008-5472.CAN-08-1044.

13.

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, García-Echeverría C.

Mol Cancer Ther. 2008 Jul;7(7):1851-63. doi: 10.1158/1535-7163.MCT-08-0017. Epub 2008 Jul 7.

14.

The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein.

Zhao X, Heng JI, Guardavaccaro D, Jiang R, Pagano M, Guillemot F, Iavarone A, Lasorella A.

Nat Cell Biol. 2008 Jun;10(6):643-53. doi: 10.1038/ncb1727. Epub 2008 May 18.

15.

N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma.

Kang J, Rychahou PG, Ishola TA, Mourot JM, Evers BM, Chung DH.

Oncogene. 2008 Jun 26;27(28):3999-4007. doi: 10.1038/onc.2008.15. Epub 2008 Feb 18.

16.

Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.

Johnsen JI, Segerström L, Orrego A, Elfman L, Henriksson M, Kågedal B, Eksborg S, Sveinbjörnsson B, Kogner P.

Oncogene. 2008 May 1;27(20):2910-22. Epub 2007 Nov 19.

PMID:
18026138
17.

Cdc6 stability is regulated by the Huwe1 ubiquitin ligase after DNA damage.

Hall JR, Kow E, Nevis KR, Lu CK, Luce KS, Zhong Q, Cook JG.

Mol Biol Cell. 2007 Sep;18(9):3340-50. Epub 2007 Jun 13.

18.

Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.

Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D, Weiss WA.

Cancer Res. 2006 Aug 15;66(16):8139-46. Erratum in: Cancer Res. 2006 Oct 15;66(20):10227.

19.

Oncogenic PI3K deregulates transcription and translation.

Bader AG, Kang S, Zhao L, Vogt PK.

Nat Rev Cancer. 2005 Dec;5(12):921-9. Review.

PMID:
16341083
20.

Id2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice.

Lasorella A, Rothschild G, Yokota Y, Russell RG, Iavarone A.

Mol Cell Biol. 2005 May;25(9):3563-74.

Supplemental Content

Support Center